

GEOVAX LABS, INC.
Condensed Consolidated Statements of Operations Information
(amounts in thousands, except common share information)

	Three Months Ended March 31,	
	2023	2022
Grant revenue	\$ -	\$ 82
Operating expenses:		
Research and development	2,819	1,331
General and administrative	1,451	1,179
	4,270	2,510
Loss from operations	(4,270)	(2,428)
Other income (expense), net	233	1
Net loss	\$ (4,037)	\$ (2,427)
Net loss per common share	\$ (0.15)	\$ (0.34)
Weighted averages shares outstanding	26,338,576	7,109,473

Condensed Consolidated Balance Sheet Information
(amounts in thousands, except common share information)

	March 31, 2023	December 31, 2022
	Assets	
Cash and cash equivalents	\$ 23,850	\$ 27,613
Other current assets	2,139	1,326
Total current assets	25,989	28,939
Property and other assets	1,415	2,409
Total assets	\$ 27,404	\$ 31,348
Liabilities and stockholders' equity		
Total liabilities	\$ 4,539	\$ 4,748
Stockholders' equity	22,865	26,600
Total liabilities and stockholders' equity	\$ 27,404	\$ 31,348
Common shares outstanding	26,443,649	26,334,953